pre-miRNA Information
pre-miRNA hsa-mir-3937   
Genomic Coordinates chrX: 39661216 - 39661321
Description Homo sapiens miR-3937 stem-loop
Comment None
RNA Secondary Structure

Mature miRNA Information
Mature miRNA hsa-miR-3937
Sequence 61| ACAGGCGGCUGUAGCAAUGGGGG |83
Evidence Experimental
Experiments Illumina
SNPs in miRNA
Mutant ID Mutant Position Mutant Source
rs1430604115 6 dbSNP
rs776622162 7 dbSNP
rs1283731816 11 dbSNP
rs1029784871 13 dbSNP
rs750525479 20 dbSNP
rs956488517 22 dbSNP
Putative Targets

miRNA Expression profile
Human miRNA Tissue Atlas
Circulating MicroRNA Expression Profiling
Gene Information
Gene Symbol NDUFA11   
Synonyms B14.7, CI-B14.7
Description NADH:ubiquinone oxidoreductase subunit A11
Transcript NM_175614   
Expression
Putative miRNA Targets on NDUFA11
3'UTR of NDUFA11
(miRNA target sites are highlighted)
>NDUFA11|NM_175614|3'UTR
   1 GCCCTGTGCCTGCCGGGACCTCCAGCCTGCAGAATGCGTCCAGAAATAAATTCTGTGTCTGTGTGTGTGTCAAAAAAAA
Target sites Provided by authors   Predicted by miRanda    DRVs    SNPs    DRVs & SNPs
miRNA-target interactions
(Predicted by miRanda)
ID Duplex structure Position Score MFE
1
miRNA  3' ggGGGUAACGAUGUC------GG-CGGACa 5'
            ||::|  ||:| |      || ||||| 
Target 5' gcCCTGTGCCTGCCGGGACCTCCAGCCTGc 3'
1 - 30 119.00 -19.90
2
miRNA  3' gggggUAACGAUGUCGGCGGACa 5'
               ||| ||::: |:|: || 
Target 5' aataaATT-CTGTGTCTGTGTGt 3'
45 - 66 93.00 -9.30
3
miRNA  3' ggggguaacgaugucggCGGaca 5'
                           |||   
Target 5' -----------------GCCctg 3'
1 - 6 60.00 -8.76
DRVs in gene 3'UTRs
Mutant ID Mutant Position Mutant Source
330235 55 ClinVar
330234 59 ClinVar
894131 63 ClinVar
COSN31784989 1 COSMIC
COSN26986182 5 COSMIC
COSN30646692 12 COSMIC
COSN508341 60 COSMIC
COSN30156544 64 COSMIC
SNPs in gene 3'UTRs
Mutant ID Mutant Position Mutant Source
rs766304743 1 dbSNP
rs763178359 3 dbSNP
rs750598527 9 dbSNP
rs1273668007 11 dbSNP
rs1206996306 12 dbSNP
rs765624733 14 dbSNP
rs762209658 15 dbSNP
rs776834428 20 dbSNP
rs955742240 26 dbSNP
rs1277796318 30 dbSNP
rs769260017 34 dbSNP
rs372606393 37 dbSNP
rs368932386 38 dbSNP
rs1433227753 46 dbSNP
rs1389824913 51 dbSNP
rs1375290940 53 dbSNP
rs771648754 55 dbSNP
rs765727153 56 dbSNP
rs191571307 59 dbSNP
rs770675936 60 dbSNP
rs779588327 61 dbSNP
rs1408789549 63 dbSNP
rs749166288 63 dbSNP
rs1469217273 67 dbSNP
Experimental Support 1 for Functional miRNA-Target Interaction
miRNA:Target ----
Validation Method
Conditions BC-3
Location of target site 3'UTR
Tools used in this research TargetScan , miRTarCLIP , Piranha
Original Description (Extracted from the article) ... PAR-CLIP data was present in GSM796039. RNA binding protein: AGO2. Condition:4-Thiouridine PAR-CLIP data was present in GSM796040. RNA binding protein: AGO2. Condition:4-Thiouridine ...

- Gottwein E; Corcoran DL; Mukherjee N; et al., 2011, Cell host & microbe.

miRNA-target interactions (Provided by authors)
ID Duplex structure Position
1
miRNA  3' ggggguAACGAUGUCGGCGGACa 5'
                |||  :| |||||||| 
Target 5' ------UUGGCGCCGCCGCCUGc 3'
1 - 17
Article - Gottwein E; Corcoran DL; Mukherjee N; et al.
- Cell host & microbe, 2011
Primary effusion lymphoma (PEL) is caused by Kaposi's sarcoma-associated herpesvirus (KSHV) and frequently also harbors Epstein-Barr virus (EBV). The expression of KSHV- and EBV-encoded microRNAs (miRNAs) in PELs suggests a role for these miRNAs in latency and lymphomagenesis. Using PAR-CLIP, a technology which allows the direct and transcriptome-wide identification of miRNA targets, we delineate the target sites for all viral and cellular miRNAs expressed in PEL cell lines. The resulting data set revealed that KSHV miRNAs directly target more than 2000 cellular mRNAs, including many involved in pathways relevant to KSHV pathogenesis. Moreover, 58% of these mRNAs are also targeted by EBV miRNAs, via distinct binding sites. In addition to a known viral analog of cellular miR-155, we show that KSHV encodes a viral miRNA that mimics cellular miR-142-3p function. In summary, this study identifies an extensive list of KSHV miRNA targets, which are likely to influence viral replication and pathogenesis.
LinkOut: [PMID: 22100165]
Experimental Support 2 for Functional miRNA-Target Interaction
miRNA:Target ----
Validation Method
Conditions LCL-BAC
Disease MIMAT0018352
Location of target site 3'UTR
Tools used in this research TargetScan , miRTarCLIP , Piranha
Original Description (Extracted from the article) ... "PAR-CLIP data was present in GSM1020023. RNA binding protein: AGO2. Condition:EBV B95-8-infected ...

- Skalsky RL; Corcoran DL; Gottwein E; Frank et al., 2012, PLoS pathogens.

Article - Skalsky RL; Corcoran DL; Gottwein E; Frank et al.
- PLoS pathogens, 2012
Epstein-Barr virus (EBV) is a ubiquitous human herpesvirus linked to a number of B cell cancers and lymphoproliferative disorders. During latent infection, EBV expresses 25 viral pre-microRNAs (miRNAs) and induces the expression of specific host miRNAs, such as miR-155 and miR-21, which potentially play a role in viral oncogenesis. To date, only a limited number of EBV miRNA targets have been identified; thus, the role of EBV miRNAs in viral pathogenesis and/or lymphomagenesis is not well defined. Here, we used photoactivatable ribonucleoside-enhanced crosslinking and immunoprecipitation (PAR-CLIP) combined with deep sequencing and computational analysis to comprehensively examine the viral and cellular miRNA targetome in EBV strain B95-8-infected lymphoblastoid cell lines (LCLs). We identified 7,827 miRNA-interaction sites in 3,492 cellular 3'UTRs. 531 of these sites contained seed matches to viral miRNAs. 24 PAR-CLIP-identified miRNA:3'UTR interactions were confirmed by reporter assays. Our results reveal that EBV miRNAs predominantly target cellular transcripts during latent infection, thereby manipulating the host environment. Furthermore, targets of EBV miRNAs are involved in multiple cellular processes that are directly relevant to viral infection, including innate immunity, cell survival, and cell proliferation. Finally, we present evidence that myc-regulated host miRNAs from the miR-17/92 cluster can regulate latent viral gene expression. This comprehensive survey of the miRNA targetome in EBV-infected B cells represents a key step towards defining the functions of EBV-encoded miRNAs, and potentially, identifying novel therapeutic targets for EBV-associated malignancies.
LinkOut: [PMID: 22291592]
CLIP-seq Support 1 for dataset GSM1020023
Method / RBP PAR-CLIP / AGO2
Cell line / Condition LCL-BAC / EBV B95-8-infected, 4-thiouridine, RNase T1
Location of target site ENST00000592634.1 | 3UTR | uuggcgccgccgccug
Tools used in this analysis TargetScan, miRTarCLIP, and Piranha
Article / Accession Series PMID: 22291592 / GSE41437
CLIP-seq Viewer Link
CLIP-seq Support 2 for dataset GSM796039
Method / RBP PAR-CLIP / AGO2
Cell line / Condition BC-3 / 4-Thiouridine
Location of target site ENST00000592634.1 | 3UTR | uuggcgccgccgccug
Tools used in this analysis TargetScan, miRTarCLIP, and Piranha
Article / Accession Series PMID: 22100165 / GSE32109
CLIP-seq Viewer Link
CLIP-seq Support 3 for dataset GSM796040
Method / RBP PAR-CLIP / AGO2
Cell line / Condition BC-3 / 4-Thiouridine
Location of target site ENST00000592634.1 | 3UTR | uuggcgccgccgccugc
Tools used in this analysis TargetScan, miRTarCLIP, and Piranha
Article / Accession Series PMID: 22100165 / GSE32109
CLIP-seq Viewer Link
MiRNA-Target Expression Profile
Dataset Pearson Correlation P-value for Pearson Correlation Spearman Correlation P-value for Spearman Correlation Samples Chart
MiRNA-Target Expression Profile (TCGA)
Tumor Pearson Correlation P-value for Pearson Correlation Spearman Correlation P-value for Spearman Correlation Samples Chart
Click to see details
Click to see details
Click to see details
Click to see details
40 hsa-miR-3937 Target Genes:
Functional analysis:
ID Target Description Validation methods
Strong evidence Less strong evidence
MIRT332487 CD81 CD81 molecule 2 2
MIRT441327 NDUFA11 NADH:ubiquinone oxidoreductase subunit A11 2 4
MIRT454032 EIF3CL eukaryotic translation initiation factor 3 subunit C like 2 2
MIRT458086 EIF3C eukaryotic translation initiation factor 3 subunit C 2 2
MIRT460785 VPS37B VPS37B, ESCRT-I subunit 2 2
MIRT463150 ZNF385A zinc finger protein 385A 2 4
MIRT467162 SREBF2 sterol regulatory element binding transcription factor 2 2 2
MIRT469618 RAI1 retinoic acid induced 1 2 4
MIRT472258 NFIC nuclear factor I C 2 2
MIRT487587 FAM83H family with sequence similarity 83 member H 2 4
MIRT489302 B4GALNT4 beta-1,4-N-acetyl-galactosaminyltransferase 4 2 4
MIRT489741 GNAI2 G protein subunit alpha i2 2 4
MIRT490038 PCSK4 proprotein convertase subtilisin/kexin type 4 2 2
MIRT490767 SRCIN1 SRC kinase signaling inhibitor 1 2 2
MIRT491750 SEMA3F semaphorin 3F 2 2
MIRT492690 PHYHIP phytanoyl-CoA 2-hydroxylase interacting protein 2 2
MIRT504843 RRP36 ribosomal RNA processing 36 2 4
MIRT510116 IRAK3 interleukin 1 receptor associated kinase 3 2 8
MIRT525313 FANCA Fanconi anemia complementation group A 2 4
MIRT569801 IGDCC3 immunoglobulin superfamily DCC subclass member 3 2 2
MIRT570224 SLC27A1 solute carrier family 27 member 1 2 2
MIRT629378 FAHD1 fumarylacetoacetate hydrolase domain containing 1 2 2
MIRT633104 CBX5 chromobox 5 2 2
MIRT645036 ATAD3C ATPase family, AAA domain containing 3C 2 2
MIRT660973 ABI2 abl interactor 2 2 2
MIRT671225 CLSTN1 calsyntenin 1 2 2
MIRT672046 SMTNL2 smoothelin like 2 2 2
MIRT677314 CPSF2 cleavage and polyadenylation specific factor 2 2 2
MIRT678290 PTRH2 peptidyl-tRNA hydrolase 2 2 2
MIRT693477 ZNF707 zinc finger protein 707 2 2
MIRT693576 PIGR polymeric immunoglobulin receptor 2 2
MIRT696832 PLLP plasmolipin 2 2
MIRT700149 RNF115 ring finger protein 115 2 2
MIRT703760 FAM118A family with sequence similarity 118 member A 2 2
MIRT705798 ALDH6A1 aldehyde dehydrogenase 6 family member A1 2 2
MIRT709105 SEPT4 septin 4 2 2
MIRT710235 ARMCX6 armadillo repeat containing, X-linked 6 2 2
MIRT711422 EPHA4 EPH receptor A4 2 2
MIRT712529 CYTH2 cytohesin 2 2 2
MIRT714081 ZNF532 zinc finger protein 532 2 2
miRNA-Drug Resistance Associations
miRNA Drug Name CID NSC FDA Effect/Pattern Detection Method Level Phenotype Condition
hsa-miR-3937 Fluorouracil 3385 NSC19893 approved resistant High Pancreatic Cancer cell line (PANC-1)
hsa-miR-3937 Gemcitabine 60750 NSC613327 approved resistant High Pancreatic Cancer cell line (PANC-1)
hsa-miR-3937 Platinum 23939 sensitive High Ovarian Cancer tissue
hsa-miR-3937 Dabrafenib 44462760 NSC764134 approved resistant High Melanoma cell line (A375, IGR37, 501Mel)
hsa-miR-3937 Vemurafenib 42611257 NSC761431 approved resistant High Melanoma cell line (A375, IGR37, 501Mel)
hsa-miR-3937 Paclitaxel 36314 NSC125973 approved resistant High Non-Small Cell Lung Cancer cell line (A549)
hsa-miR-3937 Fulvestrant 17756771 NSC719276 approved sensitive High Breast Cancer cell line (MCF-7)
hsa-miR-3937 Tamoxifen 2733525 NSC180973 approved resistant High Breast Cancer cell line (MCF-7)
hsa-miR-3937 Gemcitabine 60750 NSC613327 approved sensitive High Pancreatic Cancer cell line (AsPC-1)
hsa-miR-3937 Taxane/Cisplatin/Fluorouracil sensitive High Hypopharyngeal Squamous Cell Carcinoma tissue
hsa-miR-3937 Paclitaxel 36314 NSC125973 approved resistant High Ovarian Cancer cell line (A2780)
hsa-mir-3937 Dabrafenib 44462760 NSC764134 approved resistant cell line (A375)
hsa-mir-3937 Cisplatin 5460033 NSC119875 approved resistant cell line (BxPC3)
hsa-miR-3937 Temozolomide 5394 NSC362856 approved sensitive cell line (U251)
hsa-miR-3937 Cisplatin 5460033 NSC119875 approved sensitive cell line
hsa-miR-3937 Doxorubicin 31703 NSC123127 approved resistant cell line (HS578T)
hsa-miR-3937 Osimertinib 71496458 NSC779217 approved sensitive cell line (H1975)
hsa-miR-3937 Paclitaxel 36314 NSC125973 approved resistant cell line (A2780)
hsa-miR-3937 Cisplatin 5460033 NSC119875 approved resistant cell line (A2780)
hsa-miR-3937 Cisplatin 5460033 NSC119875 approved sensitive cell line (A549)
hsa-miR-3937 Neoadjuvant chemotherapy sensitive tissue (breast cancer)
hsa-miR-3937 Gemcitabine 60750 NSC613327 approved sensitive cell line (PANC-1) (1500 ng/ml)
hsa-miR-3937 Gemcitabine 60750 NSC613327 approved sensitive cell line (PANC-1) (100 ng/ml)
hsa-miR-3937 Docetaxel+Cisplatin+5-Fluorouracil resistant tissue (hypopharyngeal squamous cell carcinoma)
hsa-miR-3937 Paclitaxel/Docetaxel/Vinorelbine/Doxorubicin/Etoposide resistant cell line (Bads-200)

Error report submission